These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

416 related items for PubMed ID: 22251408

  • 1. Efficacy and tolerability of intravenous paricalcitol in calcitriol-resistant hemodialysis patients with secondary hyperparathyroidism: 12-month prospective study.
    Tonbul HZ, Solak Y, Atalay H, Turkmen K, Altintepe L.
    Ren Fail; 2012; 34(3):297-303. PubMed ID: 22251408
    [Abstract] [Full Text] [Related]

  • 2. Intravenous paricalcitol for treatment of secondary hyperparathyroidism in children on hemodialysis.
    Greenbaum LA, Benador N, Goldstein SL, Paredes A, Melnick JZ, Mattingly S, Amdahl M, Williams LA, Salusky IB.
    Am J Kidney Dis; 2007 Jun; 49(6):814-23. PubMed ID: 17533024
    [Abstract] [Full Text] [Related]

  • 3. Beneficial effects of better control of secondary hyperparathyroidism with paricalcitol in chronic dialysis patients.
    Capuano A, Serio V, Pota A, Memoli B, Andreucci VE.
    J Nephrol; 2009 Jun; 22(1):59-68. PubMed ID: 19229819
    [Abstract] [Full Text] [Related]

  • 4. Paricalcitol in dialysis patients with calcitriol-resistant secondary hyperparathyroidism.
    Llach F, Yudd M.
    Am J Kidney Dis; 2001 Nov; 38(5 Suppl 5):S45-50. PubMed ID: 11689387
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. A long-term, multicenter study of the efficacy and safety of paricalcitol in end-stage renal disease.
    Lindberg J, Martin KJ, González EA, Acchiardo SR, Valdin JR, Soltanek C.
    Clin Nephrol; 2001 Oct; 56(4):315-23. PubMed ID: 11680662
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Switch from calcitriol to paricalcitol in secondary hyperparathyroidism of hemodialysis patients: Responsiveness is related to parathyroid gland size.
    Vulpio C, Maresca G, Distasio E, Cacaci S, Panocchia N, Luciani G, Bossola M.
    Hemodial Int; 2011 Jan; 15(1):69-78. PubMed ID: 21223484
    [Abstract] [Full Text] [Related]

  • 10. Randomized controlled trial to compare the efficacy and safety of oral paricalcitol with oral calcitriol in dialysis patients with secondary hyperparathyroidism.
    Ong LM, Narayanan P, Goh HK, Manocha AB, Ghazali A, Omar M, Mohamad S, Goh BL, Shah S, Seman MR, Vaithilingam I, Ghazalli R, Rahmat K, Shaariah W, Ching CH, Oral Paricalcitol in ESRD Study Group.
    Nephrology (Carlton); 2013 Mar; 18(3):194-200. PubMed ID: 23311404
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Efficacy and safety of paricalcitol in children with stages 3 to 5 chronic kidney disease.
    Webb NJA, Lerner G, Warady BA, Dell KM, Greenbaum LA, Ariceta G, Hoppe B, Linde P, Lee HJ, Eldred A, Dufek MB.
    Pediatr Nephrol; 2017 Jul; 32(7):1221-1232. PubMed ID: 28332096
    [Abstract] [Full Text] [Related]

  • 17. Achievement of recommended treatment targets for bone and mineral metabolism in haemodialysis patients using paricalcitol: an observational study.
    Fernström A, Giæver J, Granroth B, Hylander B, Jensen G, Christensson A, Wikström B, Weiss L, Wrege U, Jacobson SH.
    Scand J Urol Nephrol; 2011 Apr; 45(3):196-205. PubMed ID: 21366390
    [Abstract] [Full Text] [Related]

  • 18. Paricalcitol versus calcitriol treatment for hyperparathyroidism in pediatric hemodialysis patients.
    Seeherunvong W, Nwobi O, Abitbol CL, Chandar J, Strauss J, Zilleruelo G.
    Pediatr Nephrol; 2006 Oct; 21(10):1434-9. PubMed ID: 16900383
    [Abstract] [Full Text] [Related]

  • 19. Effects of 22-oxacalcitriol and calcitriol on PTH secretion and bone mineral metabolism in a crossover trial in hemodialysis patients with secondary hyperparathyroidism.
    Ogata H, Koiwa F, Shishido K, Takahashi K, Ito H, Kinugasa E, Taguchi S.
    Ther Apher Dial; 2007 Jun; 11(3):202-9. PubMed ID: 17498002
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.